Keywords: Cancer, Metabolism, acute myeloid leukemia, serum
Motivation: Acute myeloid leukemia is marked by complex metabolic adaptations. Identifying metabolic alterations in patients may provide insights into treatment responses.
Goal(s): The study aims to explore serum metabolic profiles of newly diagnosed AML patients throughout their initial chemotherapy stages to find potential biomarkers for early drug resistance detection or prognostic predictions.
Approach: Using NMR serum metabolomics, serum samples were analyzed from AML patients at different chemotherapy stages. Multivariate statistical analysis, including PCA and OPLS-DA, were employed to detect metabolic differences.
Results: Distinct serum metabolic profiles were observed across first chemotherapy stages, primarily including various amino acid metabolism and lipid metabolism.
Impact: This study reveals serum metabolic changes in new AML patients during chemotherapy. It identifies distinct metabolic profiles, paving the way for early biomarkers of drug resistance and prognosis. Understanding these mechanisms can enhance treatment strategies and improve patient prognosis.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords